Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial
暂无分享,去创建一个
H. Heinzer | R. Bukowski | C. Szczylik | S. Oudard | G. Gravis | F. Cihon | R. Middleton | B. Escudier | Sonalee Shah | S. Anderson | T. Eisen
[1] P. Brennan,et al. The epidemiology of bladder and kidney cancer , 2007, Nature Clinical Practice Urology.
[2] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[3] Loren Lipworth,et al. Epidemiologic aspects of renal cell carcinoma. , 2006, Seminars in oncology.
[4] T. Roskams,et al. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. , 2006, Annals of Oncology.
[5] W. Bro,et al. Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). , 2006, The journal of supportive oncology.
[6] M. Huszar,et al. Efficacy of anti-angiogenic treatment of tumors in old versus young mice , 2006, Mechanisms of Ageing and Development.
[7] G. Pond,et al. Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination , 2006, Clinical Cancer Research.
[8] J. Atzpodien,et al. Age does not impair the efficacy of immunochemotherapy in patients with metastatic renal carcinoma. , 2005, Critical reviews in oncology/hematology.
[9] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[10] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[11] Tim Eisen,et al. Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma , 2004, Clinical Cancer Research.
[12] L. Siu,et al. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] E. Neulander,et al. Influence of Age on the Prognosis of Patients with Renal Cell Carcinoma (RCC) , 2002, Oncology Research and Treatment.
[14] J. Crawford,et al. Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials , 2002, Cancer.
[15] L. Balducci,et al. A case for geriatric oncology. , 2002, The Lancet. Oncology.
[16] David Cella,et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. , 2002, Journal of the National Cancer Institute.
[17] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[18] C. Coltman,et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.
[19] A. Rüfer,et al. The presentation, treatment and outcome of renal cell carcinoma in old age. , 1999, Age and ageing.
[20] A. Passaniti,et al. Altered angiogenesis underlying age-dependent changes in tumor growth. , 1994, Journal of the National Cancer Institute.
[21] D. Tulsky,et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Rademaker,et al. Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[24] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.